Trevi Therapeutics Raises $115 Million in Public Offering
Deal News | Jun 09, 2025 | Wilmer Cutler Pickering Hale and Dorr LLP
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, has successfully closed its public offering, raising approximately $115.1 million. The offering consisted of 20,010,000 shares of common stock sold at $5.75 each, including the underwriters' full exercise of their option to purchase an additional 2,610,000 shares. The WilmerHale legal team, led by Stuart Falber and supported by several other attorneys, advised Trevi in this transaction. The funds are anticipated to support the company's ongoing development of its investigational therapy, Haduvio, aimed at treating chronic cough conditions.
Sectors
- Biopharmaceutical
- Legal Advisory
- Investment Banking
Geography
- United States – Trevi Therapeutics is based in the United States, and the legal advisor WilmerHale is also a U.S.-based law firm.
Industry
- Biopharmaceutical – Trevi Therapeutics operates within the biopharmaceutical sector, focused on developing therapies for treating chronic cough and related conditions.
- Legal Advisory – WilmerHale provided legal advisory services for Trevi Therapeutics' public offering, evidencing the role of legal firms in corporate finance transactions.
- Investment Banking – Investment banks typically underwrite and facilitate public offerings like Trevi Therapeutics'.
Financials
- $115.1 Million – The total gross proceeds from Trevi Therapeutics' public offering before expenses.
- $5.75 – The price per share at which Trevi Therapeutics' common stock was offered to investors.
- 20,010,000 shares – The total number of shares issued in Trevi Therapeutics' public offering.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Trevi Therapeutics, Inc. | Target Company | Company | A clinical-stage biopharmaceutical company focused on developing treatments for chronic cough conditions. |
| Wilmer Cutler Pickering Hale and Dorr LLP | Legal Advisor | Company | A law firm that advised Trevi Therapeutics in their public offering. |